SignatureFD’s Surmodics SRDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-191
| Closed | -$5.71K | – | 3532 |
|
|
2025
Q3 | $5.71K | Hold |
191
| – | – | ﹤0.01% | 2622 |
|
|
2025
Q2 | $5.67K | Sell |
191
-31
| -14% | -$893 | ﹤0.01% | 2560 |
|
|
2025
Q1 | $6.78K | Buy |
222
+31
| +16% | +$1.04K | ﹤0.01% | 2497 |
|
|
2024
Q4 | $7.56K | Hold |
191
| – | – | ﹤0.01% | 2455 |
|
|
2024
Q3 | $7.41K | Hold |
191
| – | – | ﹤0.01% | 2457 |
|
|
2024
Q2 | $8.03K | Hold |
191
| – | – | ﹤0.01% | 2364 |
|
|
2024
Q1 | $5.6K | Buy |
+191
| New | +$6.09K | ﹤0.01% | 2500 |
|
|
2023
Q2 | – | Sell |
-25
| Closed | -$570 | – | 3363 |
|
|
2023
Q1 | $570 | Buy |
+25
| New | +$644 | ﹤0.01% | 3081 |
|
|
2022
Q3 | – | Sell |
-217
| Closed | -$8K | – | 3344 |
|
|
2022
Q2 | $8K | Buy |
217
+201
| +1,256% | +$7.79K | ﹤0.01% | 2247 |
|
|
2022
Q1 | $1K | Buy |
+16
| New | +$700 | ﹤0.01% | 3063 |
|
|
2021
Q4 | – | Sell |
-45
| Closed | -$3K | – | 3266 |
|
|
2021
Q3 | $3K | Buy |
45
+36
| +400% | +$2K | ﹤0.01% | 2556 |
|
|
2021
Q2 | $0 | Buy |
+9
| New | +$494 | ﹤0.01% | 3054 |
|
Other funds holding SRDX
SignatureFD's SRDX Position: Q4 2025 in Review
SignatureFD sold out of Surmodics (SRDX) in Q4 2025, closing a stake of 191 shares — an estimated $5.71K sold.
SignatureFD first reported a position in SRDX in Q2 2021 and held it in 12 quarters. The position peaked at $8.03K in Q2 2024. 1 fund tracked by Wall St. Rank holds SRDX as of Q4 2025.
- SignatureFD reported no remaining Surmodics position as of Q4 2025 after selling out during the quarter.
- SignatureFD sold 191 Surmodics shares in Q4 2025, an estimated $5.71K.
- SignatureFD first reported a position in Surmodics in Q2 2021 and held it in 12 quarters.
- SignatureFD's Surmodics position peaked at $8.03K in Q2 2024.
- 1 fund tracked by Wall St. Rank held Surmodics as of Q4 2025.
Based on SignatureFD's 13F filing for Q4 2025, filed 20 Jan 2026.